Barclays analyst Gena Wang lowered the firm’s price target on Intellia Therapeutics (NTLA) to $24 from $26 and keeps an Overweight rating on the shares after the company paused patient dosing for nex-z trials. The event rate was largely on par with historical studies per Barclays’ analysis, and may be transthyretin amyloidosis related, the analyst tells investors in a research note. The firm believes the temporary trial pause “could be addressable.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- AMZN, BABA, NTLA, XYZ: Cathie Wood Loads Up on Intellia, Block, Amazon & Alibaba, Cuts Stake in Shopify and Other Growth Stocks
- Cathie Wood’s ARK Investment buys 750K shares of Intellia Therapeutics today
- Intellia Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- Intellia Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
- Intellia Therapeutics’ Long-Term Study of NTLA-2001: What Investors Need to Know